To verify the prediction, dual luciferase reporter assay was conducted as reported elsewhere (18 (link)). The predicted binding mode was obtained using bioinformatic prediction by software targetscan 5.1 (http://www.targetscan.org; Whitehead Institute for Biomedical Research, Cambridge, MA, USA). PCR was performed to amplify the 3’-end fragment of lncRNA XIST containing the predicted miR-185-5p-binding site and to subclone into a pmirGLOluciferase target expression vector (Promega, USA) as the XIST wild-type vector. And the mutated miR-185-5p-binding site was constructed as XIST Mutant vector. 293T cells were co-transfected with 200 ng of either pmirGLO-XIST-wide type (WT) or pmirGLO-XIST-mutant (MUT) vector and 80 ng of miR-185-5p mimics or inhibitor and their negative controls with Lipofectamine 3000 (Invitrogen). The verification of combination between miR-185-5p and CCND2 was realized via co-transfection with pmirGLO-CCND2-WT or pmirGLO-CCND2-MUT and miR-185-5p mimics or negative control. And the relative luciferase activity was measured using Dual-luciferase Reporter Assay Kit (Progema, USA) after 48 h of transfection.